2024 / 04

Next Paper
DOI: 10.24075/brsmu.2024.034

ORIGINAL RESEARCH

Effectiveness of enriching drug treatment with systemic ozone therapy in patients with post-COVID asthenic syndrome

Soldatenko AA1, Gumenyuk LN2, Berdieva DM2, Ponomarchuk EI2
About authors

1 Rein-LTD LLC, Avicenna Clinic, Simferopol, Russia

2 S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University, Simferopol, Russia

Correspondence should be addressed: Lesya N. Gumenyuk
Bulvar Lenina, 5/7, Simferopol, 295006, Republic of Crimea; ur.liam@kuynemyg_aysel

About paper

Author contribution: Soldatenko AA — study concept and design, data acquisition; Gumenyuk LN — data analysis and interpretation, manuscript writing; Berdieva DM — data acquisition; Ponomarchuk EI — data analysis and interpretation.

Compliance with ethical standards: the study was approved by the Ethics Committee of the S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University (protocol No. 10 dated 16 October 2021), planned and conducted in accordance with the Declaration of Helsinki. The informed consent was submitted by all individuals included in the study.

Received: 2024-07-02 Accepted: 2024-07-21 Published online: 2024-08-27
|
  1. Buttery S, Philip KEJ, Williams P, Fallas A, West B, Cumella A, et al. Patient symptoms and experience following COVID-19: results from a UK-wide survey. BMJ Open Respir Res. 2021; 8 (1): e001075. DOI: 10.1136/bmjresp-2021-001075.
  2. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. GlobalPrevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022; 226: 1593–607. DOI: 10.1093/infdis/jiac136
  3. Seang S, Itani O, Monsel G, Abdi B, Marcelin AG, Valantin MA, et al. Long COVID-19 symptoms: Clinical characteristics andrecovery rate among non-severe outpatients over a six-month follow-up. Infect Dis Now. 2022; 52: 165–9. DOI: 10.1016/j.idnow.2022.02.005.
  4. Boutou AK, Asimakos A, Kortianou E, Vogiatzis I, Tzouvelekis A. Long COVID-19 pulmonary sequelae and management considerations. J Personal Med. 2021; 11 (9): 838. DOI: 10.3390/jpm11090838.
  5. Vélez-Santamaría R, Fernández-Solana J, Méndez-López F, Domínguez-García M, González-Bernal JJ, Magallón-Botaya R, et al. Functionality, physical activity, fatigue and quality of life in patients with acute COVID-19 and Long COVID infection. Sci Rep. 2023; 14: 13 (1): 19907. DOI: 10.1038/s41598-023-47218-1.
  6. Rooney S, Webster A, Paul L. Systematic Review of Changes and Recovery in Physical Function and Fitness after Severe Acute Respiratory Syndrome-Related Coronavirus Infection: Implications for COVID-19 Rehabilitation. Phys Ther. 2020; 100: 1717–29. DOI: 10.1093/ptj/pzaa129.
  7. Schultheiß C, Willscher E, Paschold L, Gottschick C, Klee B, Glasauer S, et al. From online data collection to identification of disease mechanisms: the IL1ß, IL6 and TNFα cytokine triad is associated with post-acute sequelae of COVID-19 in a digital research cohort. SSRN Electron J [Internet]. 2021. DOI: 10.2139/ssrn.3963839.
  8. Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. PostCOVID-19 syndrome: the persistent symptoms at the post-viral stage of the disease: a systematic review of the current data. Frontiers in medicine. 2021; 8: 392. DOI: 10.3389/fmed.2021.653516.
  9. Liu Z, Lv Z, Zhou X, Shi J, Hong S, Huang H, Lv L. Efficacy of traditional Chinese exercises in patients with post-COVID-19 chronic fatigue syndrome: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2022; 18: 101 (46): e31450. DOI: 10.1097/MD.0000000000031450.
  10. Kappelmann N, Dantzer R, Khandaker GM. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID19. Psychoneuroendocrinology. 2021; 131: 105295. DOI: 10.1016/j.psyneuen.2021.105295.
  11. Yin JX, Agbana YL, Sun ZS, Fei SW, Zhao HQ, Zhou XN, et al. Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis. Infect Dis Poverty. 2023; 12 (1): 43. DOI: 10.1186/s40249-023-01086-z.
  12. Zaharov DV, Buryak YU. Postkovidnye kognitivnye rasstroistva. ̆ Sovremennyĭ vzglyad na problemu, patogenez i terapiyu. Obozrenie psihiatrii i medicinskoi psihologii im. V. M. Bekhtereva. ̆ 2021; 55 (4): 97–105. Russian.
  13. Hasanova DR, ZHitkova YU, Vaskaeva GR. Postkovidnyi sindrom: ̆ obzor znanii o patogeneze, nĕ ĭropsihiatricheskih proyavleniyah i perspektivah lecheniya. Nevrologiya, neiropsihiatriya, psihosomatika. ̆ 2021; 13 (3): 93–98. Russian.
  14. Ahmedzhanova LT, Ostroumova TM, Soloha OA. Vedenie pacientov s bolevymi sindromami na fone COVID-19. Nevrologiya, neiropsihiatriya, psihosomatika. 2021; 13 (5): 96–101. Russian.̆
  15. Haibullina DH, Maksimov YuN. Astenicheskiĭ postkovidnyĭ sindrom. ̆ ZHurnal nevrologii i psihiatrii im. S. S. Korsakova. 2023; 123 (3): 61–69. DOI: 10.17116/jnevro202312303161. Russian.
  16. Naumov KM, Andreeva GO, Bazhenov DA. Differencirovannyĭ podhod k korrekcii vegetativnyh narushenii pri postkovidnom ̆ sindrome. Izvestiya Rossiiskoĭ Voenno-medicinskoĭ ̆ akademii. 2021; 40 (S4): 88–91. Russian.
  17. Bahareva ON, Baharev SA, Konov KYu, Vanteev DA, Lyagushin RS. Nevrologicheskie proyavleniya postkovidnogo sindroma i vozmozhnosti reabilitacii. Lazernaya medicina. 2021; 25 (1): 16– 20. Russian.
  18. AlMogbel AA, Albarrak MI, AlNumair SF. Ozone Therapy in the Management and Prevention of Caries. Cureus. 2023; 15 (4): e37510. DOI: 10.7759/cureus.37510.
  19. Bette M, Cors E, Kresse C, Schütz B. Therapeutic treatment of superoxide dismutase 1 (G93A) amyotrophic lateral sclerosis model mice with medical ozone decelerates trigeminal motor neuron degeneration, attenuates microglial proliferation, and preserves monocyte levels in mesenteric lymph nodes. Int J Mol Sci. 2022; 23: 3403. DOI: 10.3390/ijms23063403.
  20. Wang Z, Zhang A, Meng W, Wang T, Li D, Liu Z, Liu H. Ozone protects the rat lung from ischemia-reperfusion injury by attenuating NLRP3-mediated inflammation, enhancing Nrf2 antioxidant activity and inhibiting apoptosis. Eur J Pharmacol. 2018; 835: 82–93. DOI: 10.1016/j.ejphar.2018.07.059.
  21. Sallustio F, Cardinale G, Voccola S, Picerno A, Porcaro P, Gesualdo L. Ozone eliminates novel coronavirus Sars-CoV-2 in mucosal samples. New Microbes New Infect. 2021; 43: 100927. DOI: 10.1016/j.nmni.2021.100927.
  22. Zheng Z, Dong M, Hu K. A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19. J Med Virol. 2020; 92: 2348–50. DOI: 10.1002/jmv.26040.
  23. Díaz-Soto MT, Pérez AF, Vaillant JD, Mallok A, Viebahn-hänsler R, Menéndez C, et al. Ozone Therapy Ameliorates Nervous System Disorders and Oxidative Stress in Patients During Ethanol Withdrawal - A Pilot Study, Ozone: Science & Engineering. 2012; 34 (6): 432–37. DOI: 10.1080/01919512.2012.717858.
  24. Rudnev IE, Proshchenko IV, Maksimova NE. Ozonoterapiya pri trevozhnyh i depressivnyh rasstrojstvah s panicheskimi atakami. Verhnevolzhskij medicinskij zhurnal. 2018; 17 (4): 18–21. Russian.
  25. Franzini M, Valdenassi L, Ricevuti G, Chirumbolo S, Depfenhart M, Bertossi D, Tirelli U. Oxygen-ozone (O2–O3) immunoceutical therapy for patients with COVID-19 Preliminary evidence reported. Int Immunopharmacol. 2020; 88: 106879. DOI: 10.1016/j.intimp.2020.106879.
  26. Shah M, Captain J, Vaidya V, Kulkarni A, Valsangkar K, Nair PMK, Ganu G. Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study). Int Immunopharmacol. 2021; 91: 107301. DOI: 10.1016/j.intimp.2020.107301.
  27. Fernandez-Cuadros ME, Albaladejo-Florin MJ, Alava-Rabasa S, Usandizaga-Elio I, Martinez-Quintanilla Jimenez D, Pena-Lora D, et al. Effect of Rectal ozone (O3) in severe COVID-19 pneumonia: preliminary results. SN Compr Clin Med. 2020; 2: 1328–36. DOI: 10.1007/s42399-020-00374-1.
  28. Cvetkova AV, Koneva ES, Kostenko AA, Bisheva DR, Sidyakina IV, Konev SM, i dr. Rol' sistemnoi ozonoterapii v reabilitacii pacientov, ̆ perenesshih COVID-19. Voprosy kurortologii, fizioterapii i lechebnoĭ fizicheskoĭ kul'tury. 2022; 99 (4–2): 22–29. DOI: 10.17116/kurort20229904222. Russian.
  29. Gumenyuk LN, Ternovaya AI, Parshikova VO, Hudyakova AS, Dzheparov EF. Effektivnost' primeneniya ozonoterapii u pacientov s postkovidnym sindromom na etape sanatorno-kurortnogo lecheniya. Medicina. Sociologiya. Filosofiya. Prikladnye issledovaniya. 2023; 3: 59–65. Russian.
  30. Tanashyan MM, Kuznecova PI, Raskurazhev AA, Zaslavskaya KYa. Struktura postkovidnogo astenicheskogo sindroma. Perspektivy korrekcii. Terapevticheskiĭ arhiv. 2023; 95 (5): 418–24. DOI: 10.26442/00403660.2023.05.202224. Russian.
  31. Tanashyan MM, Raskurazhev AA, Kuznecova PI, Belyj PA, Zaslavskaya KYa. Perspektivy i vozmozhnosti terapii pacientov s astenicheskim sindromom posle perenesennoj novoj koronavirusnoj infekcii COVID-19. Terapevticheskij arhiv. 2022; 94 (11): 1285–93. DOI: 10.26442/00403660.2022.11.201981. Russian.
  32. Smets EMA, Garssen B, Bonke B, De Haes JCJM. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. Journal of Psychosomatic Research. 1995; 39 (5): 315–25.
  33. Kopecek M, Stepankova H, Lukavsky J, Ripova D, Nikolai Т, Bezdicek O. Montreal Cognitive Assessment (MoCA): Normative Data for Old and Very Old Czech Adults// Applied Neuropsychology: Adult. 2016; 1–7. DOI: 10.1080/23279095.2015.1065261.
  34. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28 (2): 193–213. DOI: 10.1016/0165-1781(89)90047-4.
  35. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959; 32: 50–55. DOI: 10.1111/j.2044-8341.1959.tb00467.x.
  36. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007; 4 (7): 28–37.
  37. Alonso-Domínguez J, Gallego-Rodríguez M, Martínez-Barros I, Calderón-Cruz B, Leiro-Fernández V, Pérez-González A, Poveda E. High Levels of IL1β, TNFα and MIP-1α One Month after the Onset of the Acute SARS-CoV-2 Infection, Predictors of Post COVID-19 in Hospitalized Patients. Microorganisms. 2023; 26: 11 (10): 2396. DOI: 10.3390/microorganisms11102396.
  38. Majolo F, Silva GL, Vieira L, Anli C, Timmers LF, Laufer S, Goettert MI. Neuropsychiatric disorders and COVID-19: what we know so far. Pharmaceuticals. 2021; 14 (9): 933. DOI: 10.3390/ph14090933.
  39. Ganong WF. Circumventricular organs: definition and role in the regulation of endocrine and autonomic function. Clin Exp Pharmacol Physiol. 2000; 27: 422–7. DOI: 10.1046/j.1440-1681.2000.03259.x.
  40. Evrensel A, Ünsalver BÖ, Ceylan ME. Neuroinflammation, Gut-Brain Axis and Depression. Psychiatry Investig. 2020; 17 (1): 2–8. DOI: 10.30773/pi.2019.08.09.
  41. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Front Immunol. 2020; 11: 1708. DOI: 10.3389/fimmu.2020.01708.
  42. Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, Hirano T. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020; 40: 37. DOI: 10.1186/s41232-020-00146-3.
  43. Scassellati C, Galoforo AC, Bonvicini C, Esposito C, Ricevuti G. Ozone: a natural bioactive molecule with antioxidant property as potential new strategy in aging and in neurodegenerative disorders. Ageing Res Rev. 2020; 63: 101138. DOI: 10.1016/j.arr.2020.101138.
  44. Kim AN, Jeon W‐K, Lee JJ, Kim B‐C. Up‐regulation of heme oxygenase‐1 expression through CaMKII‐ERK1/2‐Nrf2 signaling mediates the anti–inflammatory effect of bisdemethoxycurcumin in LPS‐stimulated macrophages. Free Radic Biol Med. 2010; 49 (3): 323–33. DOI: 10.1016/j.freeradbiomed.2010.04.015.
  45. Ahmed SM, Luo L, Namani A, Wang XJ, Tang X. Nrf2 signaling pathway: pivotal roles in inflammation. BBA–Mol Basis Dis. 2017; 1863 (2): 585–97. DOI: 10.1016/j.bbadis.2016.11.005.
  46. Ahmed SM, Luo L, Namani A, Wang XJ, Tang X. Nrf2 signaling pathway: Pivotal roles in inflammation. Biochim Biophys Acta Mol Basis Dis. 2017; 1863 (2): 585–97. DOI: 10.1016/j.bbadis.2016.11.005.
  47. Cenci A, Macchia I, La Sorsa V, Sbarigia C, Di Donna V, Pietraforte D. Mechanisms of Action of Ozone Therapy in Emerging Viral Diseases: Immunomodulatory Effects and Therapeutic Advantages With Reference to SARS-CoV-2. Front Microbiol. 2022; 21 (13): 871645. DOI: 10.3389/fmicb.2022.871645.
  48. Tirelli U, Franzini M, Valdenassi L, Pisconti S, Taibi R, Torrisi C, et al. Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozoneautohemotherapy - preliminary results on 100 patients. Eur Rev Med Pharmacol Sci. 2021; 25 (18): 5871–5. DOI: 10.26355/eurrev_202109.